drugset / Trial / NCT05207371
Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase I Part : Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II. Phase II Part : Explore the efficacy and safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer at the recommended dose of GAIA-102 decided in the Phase I part.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2024-09-01
- Completion
- 2026-03-06
Outcome
Outcome not reported
Stopped: “Decision based on the development company's development policy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GAIA-102 | Cell therapy | 2e+08 cells | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |